Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Autolus Limited
Hoffmann-La Roche
Gilead Sciences
Syndax Pharmaceuticals
National Cancer Institute (NCI)
Seagen Inc.
BeOne Medicines
Hoffmann-La Roche
Gamida Cell ltd
Children's Oncology Group
Merck Sharp & Dohme LLC
Acerta Pharma BV
BeOne Medicines
Acerta Pharma BV
Gustave Roussy, Cancer Campus, Grand Paris
Acerta Pharma BV
Hoffmann-La Roche
Eli Lilly and Company
Gilead Sciences
Incyte Corporation
Gilead Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Takeda
Kura Oncology, Inc.
Hoffmann-La Roche
Celgene
Novartis
Karyopharm Therapeutics Inc
Genentech, Inc.
Acerta Pharma BV
Celgene
Genmab
Celgene
Blueprint Medicines Corporation
Eli Lilly and Company
BeiGene
Checkpoint Therapeutics, Inc.
Pfizer
Acerta Pharma BV
BeiGene
BeiGene
BeiGene
Juno Therapeutics, a Subsidiary of Celgene
Amgen
Amgen
Kyowa Kirin Co., Ltd.